MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Trevor Douglass, DC; Jennifer Bowen; Kyle Hamilton; Chris DeMars

Audience: Alice Wyse Jackson*, Amgen; P Reeger Cortell*, Southern Oregon Bariatric Center; LeslieAnn Hayward Story*, OHSU; Annie Griffin*, US Citizen; Yolanda Clay*, Obesity Action Coalition; Kristal Hartman*, Obesity Action Coalition; Kat Khachatourian*, Novo Nordisk; Josh Akers*, Eli Lilly; Cody Gerber*, Rhythm Pharmaceutical; Jamie Tobitt*, Apellis Pharmaceuticals: Alexa Erickson, Umpqua Health; Bill Reid, Lilly; Brandie Feger, Advanced Health CCO; Bryan Armstrong, CareOregon; Carissa Kemp, American Diabetes Associations; Chris Ferrin, IHN; Drew Larson, OHSU Health; Jeff Forshey, Rhythm; Jeff White, Sumitomo; Jenny Todenhagen, Genentech; Kaitlyn Molina, Samaritan Health Plan; Lief Bruce, Novo Nordisk; Lisa Pulver, J&J; Lynda Finch, Biogen; Margaret Smith-Isa, OHA; Mark England, Mercer; Gary Parenteau, Dexcel; Matt Worthy, OHSU; Melissa Bailey Hall, Lilly; Melissa Abbott, Eisai; Norm Navarro, PHP; Sabrina Riggs, Novo Nordisk; Shauna Wick, Trillium Community Health Plan; Stacy Hamm, Genentech; Steve Hall, Genentech; Tiina Andrews, UHA; Katie Scheelar; Andi Stratton, Krystal Biotech; Reeger Cortell, FNP; Camille Kerr, Regeneron; Chrystal Jones; Baltazar Diaz, PacificSource Health Plans; Sehila Albeke, Ken Liu, Madrigal Pharma

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and February 2024 Minutes presented by Roger Citron, RPh
   ACTION: Motion to approve, 2nd, all in favor
D. Department Update provided by Andrew Gibler, PharmD
E. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. Preferred Drug List (PDL): Insulin Literature Scan - Deferred to June P&T Meeting
B. Vascular Endothelial Growth Factor (VEGF) Class Update & New Drug Evaluation (NDE)
   Recommendation:
   - No PDL recommendations based on clinical evidence
   - Evaluate costs in executive session
C. PDL Old Business: Inhalers for Asthma and COPD Class Update
   Recommendation:
   - Evaluate costs in executive session
D. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Iwilfin™ (eflornithine); and Amtagvi™ (lifileucel) to Table 1 in the Oncology
     Agents PA criteria
   ACTION: Motion to approve, 2nd, all in favor

III. DUR NEW BUSINESS

A. Orphan Drug Policy Updates: Sarah Servid, PharmD
   Recommendation:
   - Simplify PA criteria by linking to FDA labeling instead of including details in the PA
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of
     Adzynma (ADAMTS13, recombinant-krhn); Rethymic® (allogeneic processed thymus
     tissue-agdc); Filsuhev (birch triterpenes); Vyjuvek™ (beremagene geperpavec-svdt); Skysona®
     (elivaldogene autotemcel); and Recorlev® (levoketoconazole) based on FDA-approved label
   ACTION: Motion to approve, 2nd, all in favor

B. Tepezza® (Teprotumumab) PA Update: Sara Fletcher, PharmD
   Recommendation:
IV. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Drugs for Weight Loss Drug Effectiveness Review Project (DERP) Summary and Glucagon-like Peptide-1 (GLP1) Receptor Agonist (RA) Literature Scan: Dee Weston & Kathy Sentena, PharmD

Recommendations:
- Recommend the OHA perform a budgetary analysis and identify a funding plan to consider opening coverage for weight management drugs
- Establish clinically appropriate minimum standards for required diet and lifestyle modifications
- Implement the proposed PA for coverage under the EPSDT
- No changes to the PDL for GLP1 and dual GLP1-GIP RAs are recommended based on review of the evidence
- Evaluate costs in the executive session

Public Comment: Reeger Cortell, S. Oregon Bariatric Center; LesleAnn Hayward Story, OHSU; Anne Griffin, US Citizen; Yolanda Clay, Obesity Action Coalition (OAC); Kristal Hartman, OAC; Kat Khachatourian, Novo Nordisk; Josh Akers, Eli Lilly; and Cody Gerber, Rhythm Pharmaceutical

ACTION: The Committee modified the proposed PA criteria for coverage under EPSDT down to 6 years of age and to add Orlistat to the tables

Motion to approve, 2nd, all in favor

B. Drugs for Bowel Prep Class Review: Deanna Moretz, PharmD

Recommendations:
- Add the “Bowel Preparations” class to the PDL and make at least one PEG product and one saline-laxative preferred
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. Antivirals for SARS-CoV2 Class Review: Deanna Moretz, PharmD

Recommendations:
- Add the “COVID-19 Antivirals” class to the PDL and designate ritonavir-boosted nirmatrelvir and remdesivir preferred
- If approved by the FDA, make molnupiravir preferred on the PDL with age restrictions in patients <18 years old due to risk of adverse effects
ACTION: Motion to approve, 2nd, all in favor

D. Syforve® (pegcetacoplan) & Izervay™ (avacincaptad) NDEs: Dave Engen, PharmD
Recommendations:
- Add the “Ophthalmologic Complement Inhibitors” class to the PDL and designate pegcetacoplan and avacincaptad pegol as non-preferred
- Implement the proposed PA criteria to limit use to the FDA approved indications
Public Comment: Jamie Tobitt, Apellis Pharmaceuticals
ACTION: Motion to approve, 2nd, all in favor

E. Phosphorus Binder Class Update and NDE: Deanna Moretz, PharmD
Recommendations:
- Revise name of PDL class to “phosphate binders and absorption inhibitors”
- Maintain tenapanor as nonpreferred and amend PA criteria to allow coverage for clinically appropriate use as add-on therapy in hyperphosphatemia and CKD
- Evaluate costs in executive session
ACTION: Motion in executive session

V. EXECUTIVE SESSION

Members Present: Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Andrew Gibler, PharmD; Lan Starkweather, PharmD; Brandon Wells

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. VEGF Class Update & NDE
Recommendation: No PDL changes recommended
ACTION: Motion to approve, 2nd, all in favor

B. Maintenance Inhalers for Asthma/COPD
Recommendations: Make tiotropium capsules non-preferred
ACTION: Motion to approve, 2nd, all in favor

C. Drugs for Weight Loss DERP Summary & GLP1 RA Lit Scan
Recommendations: No PDL changes recommended
ACTION: Motion to approve, 2nd, all in favor

D. Drugs for Bowel Prep Class Review  
Recommendations: Make Moviprep powder pack, SuTab tablet, and Clenpiq solution non-preferred; and make other bowel prep agents preferred  
ACTION: Motion to approve, 2nd, all in favor

E. Phosphorus Binder Class Update & NDE  
Recommendation: Make sevelamer HCl tablets non-preferred  
ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN